Zhi Tong Cai Jing·2025-10-31 02:09Core Viewpoint - Spring Medical (01858) experienced a significant stock increase of over 10%, attributed to strong financial performance in the first three quarters of 2025, with notable growth in revenue and net profit [1] Financial Performance - The company reported a revenue of 756 million yuan, representing a year-on-year increase of 48.75% [1] - Net profit attributable to shareholders reached 192 million yuan, showing a substantial year-on-year growth of 213.21% [1] - In the third quarter alone, revenue was 268 million yuan, reflecting a remarkable year-on-year growth of 109.51% [1] - The net profit for the third quarter was 77.06 million yuan, marking a turnaround from losses to profitability [1] Market Expansion and Competitive Advantage - Huatai Securities noted that the company's rapid growth in the third quarter is primarily due to its steady progress in international market expansion and increasing export revenue [1] - The company has successfully passed CE annual system audits and supervision audits for its hip, knee, and spine product lines, indicating strong international market competitiveness [1] - The knee prosthesis system received FDA 510(K) approval, showcasing the company's technological advantages and establishing a foundation for sustained international sales growth [1]